Pomalyst
Payments companies reported to CMS as associated with Pomalyst. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pomalyst, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pomalyst
These are the largest totals companies reported as associated with Pomalyst. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Robert Vescio | West Hollywood, CA | Hematology & Oncology | $55,376.98 |
| Suzanne Fanning | Greenville, SC | Hematology & Oncology | $51,769.91 |
| Michael Dugan | Indianapolis, IN | Hematology & Oncology | $48,539.27 |
| Hakan Kaya | Spokane, WA | Medical Oncology | $44,878.69 |
| Michael Schuster | New York, NY | Hematology & Oncology | $33,970.58 |
| Imadeddine Tabbara | Washington, DC | Hematology & Oncology | $32,038.43 |
| Ehsan Malek | Buffalo, NY | Medical Oncology | $27,764.92 |
| Kelty Baker | Houston, TX | Hematology (Internal Medicine) | $27,147.16 |
| Edward Pearson | Dallas, TX | Hematology & Oncology | $22,640.17 |
| Jayesh Mehta | Chicago, IL | Hematology (Internal Medicine) | $22,328.32 |
Prescribed Pomalyst?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.